Fresenius To Upgrade I.V. Fluid Units To European Standard

Fresenius Kabi, the European leader in infusion and nutrition therapy, which has strong market presence in emerging markets including India, would upgrade its manufacturing facilities all across the world to European quality standards. As part of this global facility standardization, the company's Indian facility located at Ranjangaon near Pune is also getting upgraded to the EU quality norms.

Fresenius is currently one of the three leading IV fluid manufacturing companies in India, which is enjoying more than 30 per cent of the market share with 70 per cent of corporate specially hospitals in the country in its clientele list. With its comprehensive range of products in combination with responsive services, the company has a unique position in its business fields.

In addition to the manufacturing plant in Pune, the Indian subsidiary has a dedicated contract manufacturing set up with the Kerala based Gujarat Injectables Ltd as well in the country.

The product portfolio of the company in the field of infusion therapy comprises intravenous solutions, active ingredients and medical - technical products. It includes products for fluid and blood volume replacement and anaesthetic agents for general anaesthesia. Infusion therapy products are essential medications, which are mainly used in surgery, intensive and emergency medicine. While in the nutrition therapy, Fresenius Kabi provides patients with parenteral and enteral nutrition including the medical-technical products, which are required during a stay in hospital and in the ambulatory environment.

(Ref : CHRONICLE PHARMABIZ Dated February 10, 2005)

Medtronic Offers Insulin Pumps In Indian Market

Medtronic offers Model 508 series insulin pumps to help insulin dependent patients improve their blood sugar control. In fact, maintaining near normal blood sugar levels using predictable, rapid acting insulin, delivered precisely and on command by an insulin pump can help patients reduce their risk of diabetes related complications, including blindness, kidney failure, amputation, impotence and heart disease.

Once patients being using an insulin pump, 97 per cent remain on pump therapy. Results from a randomized, controlled, crossover trial in five countries throughout Europe recently demonstrated that pump users achieved significantly better overall quality of life compared to those using injection therapy. The pump users had less diabetes related worry, higher treatment satisfaction and improved flexibility in terms of eating habits, lifestyle and sleep patterns.

(Ref : Express Pharma Pulse Dated December 23, 2004)